Antisoma restructures, considers sale following AS1413 failure
This article was originally published in Scrip
Executive Summary
Antisoma is considering all options to maximise shareholder value, including a possible sale of the company, as it picks up the pieces following the recent Phase III failure of lead development programme AS1413 in secondary acute myeloid leukaemia (AML) (scripintelligence.com, 31 January 2011).